Research Focus: Targeting CEACAM5 With Novel Antibody–Drug Conjugates in Nonsquamous Non-Small-Cell Lung Cancer

Gain insight from expert faculty as they discuss the importance of molecular testing in NSCLC, emerging investigational antibody–drug conjugates targeting CEAMCAM5, and the potential role in nonsquamous NSCLC with a text module, downloadable slideset, and expert commentary.

Share

Program Content

Activities

Targeting CEACAM5 in NSCLC
Research Focus: Targeting CEACAM5 With Novel Antibody‒Drug Conjugates in Nonsquamous Non-Small-Cell Lung Cancer
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

Expires: June 08, 2024

Activities

Targeting CEACAM5 in NSCLC
Research Focus: Targeting CEACAM5 With Novel Antibody-Drug Conjugates in Nonsquamous Non-Small-Cell-Lung Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2023

Activities

ADCs Targeting CEACAM5 in NSCLC
The Potential of Antibody‒Drug Conjugates Targeting CEACAM5 in NSCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 30, 2023

Faculty

cover img faculity

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Sanofi.

Sanofi